Sanofi Qfitlia And Cablivi Approved By NMPA In China Expanding Care For Rare Hematologic Diseases Including Hemophilia And aTTP

Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases

• Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a year
• Cablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder